Logo image of ABEO

ABEONA THERAPEUTICS INC (ABEO) Stock Fundamental Analysis

NASDAQ:ABEO - Nasdaq - US00289Y2063 - Common Stock - Currency: USD

6.16  -0.08 (-1.28%)

After market: 6.3 +0.14 (+2.27%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ABEO. ABEO was compared to 559 industry peers in the Biotechnology industry. Both the profitability and financial health of ABEO have multiple concerns. While showing a medium growth rate, ABEO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ABEO has reported negative net income.
In the past year ABEO has reported a negative cash flow from operations.
ABEO had negative earnings in each of the past 5 years.
ABEO had a negative operating cash flow in each of the past 5 years.
ABEO Yearly Net Income VS EBIT VS OCF VS FCFABEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ABEO has a Return On Assets (-44.47%) which is comparable to the rest of the industry.
ABEO has a Return On Equity (-106.74%) which is in line with its industry peers.
Industry RankSector Rank
ROA -44.47%
ROE -106.74%
ROIC N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ABEO Yearly ROA, ROE, ROICABEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

ABEO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABEO Yearly Profit, Operating, Gross MarginsABEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ABEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABEO has been increased compared to 1 year ago.
ABEO has more shares outstanding than it did 5 years ago.
ABEO has a worse debt/assets ratio than last year.
ABEO Yearly Shares OutstandingABEO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ABEO Yearly Total Debt VS Total AssetsABEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ABEO has an Altman-Z score of -9.83. This is a bad value and indicates that ABEO is not financially healthy and even has some risk of bankruptcy.
ABEO has a worse Altman-Z score (-9.83) than 73.35% of its industry peers.
A Debt/Equity ratio of 0.27 indicates that ABEO is not too dependend on debt financing.
ABEO has a Debt to Equity ratio of 0.27. This is in the lower half of the industry: ABEO underperforms 71.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z -9.83
ROIC/WACCN/A
WACC16.01%
ABEO Yearly LT Debt VS Equity VS FCFABEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

ABEO has a Current Ratio of 4.90. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ABEO (4.90) is comparable to the rest of the industry.
A Quick Ratio of 4.90 indicates that ABEO has no problem at all paying its short term obligations.
ABEO has a Quick ratio of 4.90. This is comparable to the rest of the industry: ABEO outperforms 53.49% of its industry peers.
Industry RankSector Rank
Current Ratio 4.9
Quick Ratio 4.9
ABEO Yearly Current Assets VS Current LiabilitesABEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 75.38% over the past year.
Looking at the last year, ABEO shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)75.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.31%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ABEO will show a very strong growth in Earnings Per Share. The EPS will grow by 29.18% on average per year.
ABEO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 420.51% yearly.
EPS Next Y91.7%
EPS Next 2Y45.14%
EPS Next 3Y38.16%
EPS Next 5Y29.18%
Revenue Next Year25007.8%
Revenue Next 2Y3160.88%
Revenue Next 3Y1148.98%
Revenue Next 5Y420.51%

3.3 Evolution

ABEO Yearly Revenue VS EstimatesABEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ABEO Yearly EPS VS EstimatesABEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

ABEO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 33.18, ABEO can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ABEO indicates a rather cheap valuation: ABEO is cheaper than 90.16% of the companies listed in the same industry.
ABEO is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 33.18
ABEO Price Earnings VS Forward Price EarningsABEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABEO Per share dataABEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ABEO's earnings are expected to grow with 38.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.14%
EPS Next 3Y38.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABEO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABEONA THERAPEUTICS INC

NASDAQ:ABEO (6/13/2025, 8:00:00 PM)

After market: 6.3 +0.14 (+2.27%)

6.16

-0.08 (-1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners63.16%
Inst Owner Change-5.43%
Ins Owners5.94%
Ins Owner Change16.93%
Market Cap315.15M
Analysts86.67
Price Target20.33 (230.03%)
Short Float %12.29%
Short Ratio3.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.23%
Min EPS beat(2)35.24%
Max EPS beat(2)61.23%
EPS beat(4)3
Avg EPS beat(4)48.69%
Min EPS beat(4)-52.88%
Max EPS beat(4)151.17%
EPS beat(8)4
Avg EPS beat(8)-1.17%
EPS beat(12)7
Avg EPS beat(12)25.62%
EPS beat(16)10
Avg EPS beat(16)17.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.09%
PT rev (3m)25.34%
EPS NQ rev (1m)-5.82%
EPS NQ rev (3m)1.77%
EPS NY rev (1m)0%
EPS NY rev (3m)88.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)12.63%
Revenue NY rev (3m)26.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 33.18
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.61
P/tB 7.61
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)0.19
Fwd EY3.01%
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.47%
ROE -106.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 104.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.9
Quick Ratio 4.9
Altman-Z -9.83
F-Score2
WACC16.01%
ROIC/WACCN/A
Cap/Depr(3y)32.9%
Cap/Depr(5y)51.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.31%
EPS Next Y91.7%
EPS Next 2Y45.14%
EPS Next 3Y38.16%
EPS Next 5Y29.18%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year25007.8%
Revenue Next 2Y3160.88%
Revenue Next 3Y1148.98%
Revenue Next 5Y420.51%
EBIT growth 1Y-37.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-44.18%
OCF growth 3YN/A
OCF growth 5YN/A